IS4147A - Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum - Google Patents

Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum

Info

Publication number
IS4147A
IS4147A IS4147A IS4147A IS4147A IS 4147 A IS4147 A IS 4147A IS 4147 A IS4147 A IS 4147A IS 4147 A IS4147 A IS 4147A IS 4147 A IS4147 A IS 4147A
Authority
IS
Iceland
Prior art keywords
production
benzodiazepine derivatives
benzodiazepine
derivatives
Prior art date
Application number
IS4147A
Other languages
English (en)
Inventor
Finch Harry
Shah Pritom
Arthur Ellis Carr Robin
Original Assignee
Glaxo Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Inc filed Critical Glaxo Inc
Publication of IS4147A publication Critical patent/IS4147A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
IS4147A 1993-04-15 1994-04-11 Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum IS4147A (is)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB939307833A GB9307833D0 (en) 1993-04-15 1993-04-15 Modulators of cholecystokinin and gastrin

Publications (1)

Publication Number Publication Date
IS4147A true IS4147A (is) 1994-10-16

Family

ID=10733915

Family Applications (2)

Application Number Title Priority Date Filing Date
IS4148A IS4148A (is) 1993-04-15 1994-04-11 Hliðstæð aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum
IS4147A IS4147A (is) 1993-04-15 1994-04-11 Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum

Family Applications Before (1)

Application Number Title Priority Date Filing Date
IS4148A IS4148A (is) 1993-04-15 1994-04-11 Hliðstæð aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum

Country Status (34)

Country Link
US (2) US5646140A (is)
EP (1) EP0694039B1 (is)
JP (1) JP3406317B2 (is)
KR (1) KR100364948B1 (is)
CN (1) CN1058487C (is)
AP (2) AP512A (is)
AT (1) ATE198894T1 (is)
AU (1) AU681139B2 (is)
CA (1) CA2158973C (is)
CZ (1) CZ286695B6 (is)
DE (1) DE69426624T2 (is)
DK (1) DK0694039T3 (is)
EC (1) ECSP941066A (is)
ES (1) ES2154674T3 (is)
FI (1) FI954853A0 (is)
GB (1) GB9307833D0 (is)
GR (1) GR3035641T3 (is)
HK (1) HK1003943A1 (is)
HU (1) HU223467B1 (is)
IL (2) IL109316A (is)
IS (2) IS4148A (is)
MY (2) MY131569A (is)
NO (1) NO311133B1 (is)
NZ (1) NZ265272A (is)
OA (1) OA10355A (is)
PE (2) PE50994A1 (is)
PH (1) PH30897A (is)
PL (1) PL178790B1 (is)
PT (1) PT694039E (is)
RU (1) RU2135486C1 (is)
SK (1) SK281211B6 (is)
TW (1) TW487703B (is)
WO (1) WO1994024149A1 (is)
ZA (2) ZA942571B (is)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5776929A (en) * 1993-12-28 1998-07-07 Shionogi & Co., Ltd. Benzodiazepine derivative
CZ286764B6 (en) * 1994-04-14 2000-06-14 Glaxo Wellcome Inc 5-Heterocyclo-1,5-benzodiazepine derivatives, process of their preparation and pharmaceutical preparation containing thereof
US5739129A (en) * 1994-04-14 1998-04-14 Glaxo Wellcome Inc. CCK or gastrin modulating 5-heterocyclic-1, 5 benzodiazepines
AU2446295A (en) * 1994-04-15 1995-11-10 Glaxo Inc. A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
PE27497A1 (es) * 1994-04-15 1997-08-07 Glaxo Inc Derivados de 1,5 benzodiazepina
GB9420763D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc Acetamide derivatives
GB9420748D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
US5780464A (en) * 1994-10-14 1998-07-14 Glaxo Wellcome Inc. Enteric coated compositions of 1,5-benzodiazepine derivatives having CCK antagonistic or agonistic activity
GB9420747D0 (en) * 1994-10-14 1994-11-30 Glaxo Inc 1,5 benzodiazepine derivatives
US5910495A (en) * 1994-10-14 1999-06-08 Glaxo Wellcome Inc. Use of 1,5-benzo b!1,4-diazepines to control gastric emptying
DE69637211T2 (de) 1995-12-11 2008-05-08 New England Medical Center Hospitals, Inc., Boston Test für und verwendungen von liganden von peptidhormonrezeptoren.
US5750353A (en) * 1995-12-11 1998-05-12 New England Medical Center Hospitals, Inc. Assay for non-peptide agonists to peptide hormone receptors
DE69724644D1 (de) * 1996-12-10 2003-10-09 Zeria Pharm Co Ltd 1,5-benzodiazepinderivate
NZ525022A (en) 1997-04-15 2004-05-28 Csir Pharmaceutical compositions having appetite suppressant activity
AR022044A1 (es) * 1999-05-06 2002-09-04 Glaxo Group Ltd Derivados de 1,5-benzodiazepina
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
US6768024B1 (en) 2000-08-04 2004-07-27 Lion Bioscience Ag Triamine derivative melanocortin receptor ligands and methods of using same
US20020180095A1 (en) * 2001-05-29 2002-12-05 Berard Steven O. Thermally conductive carbon fiber extrusion compounder and method of using same
US7074805B2 (en) * 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2476936A1 (en) * 2002-02-20 2003-08-28 Chih-Hung Lee Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (vr1) receptor
US6933311B2 (en) * 2003-02-11 2005-08-23 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
US7015233B2 (en) 2003-06-12 2006-03-21 Abbott Laboratories Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor
EP1753766A1 (en) * 2004-05-25 2007-02-21 Pfizer Products Inc. Tetraazabenzo(e)azulene derivatives and analogs thereof
CN1333077C (zh) * 2005-04-15 2007-08-22 华南农业大学 缩胆囊素活性片段的串联表达及其应用
MX2009002018A (es) * 2006-08-25 2009-03-05 Abbott Lab Derivados de indazol que inhiben vanilloide-1 potencial de receptor pasajero (trpv1) y usos de los mismos.
JP2010513557A (ja) 2006-12-20 2010-04-30 アボット・ラボラトリーズ 疼痛治療のためのｔｒｐｖ１バニロイド受容体アンタゴニストとしてのｎ−（５，６，７，８−テトラヒドロナフタレン−１−イル）尿素誘導体および関連化合物
CA2719018A1 (en) * 2008-03-20 2009-09-24 Abbott Laboratories Methods for making central nervous system agents that are trpv1 antagonists
CN103102285B (zh) * 2013-01-30 2015-07-29 淮阴师范学院 对氨基苯乙腈的制备方法
EP3071205B1 (en) 2013-11-18 2020-02-05 Forma Therapeutics, Inc. Benzopiperazine compositions as bet bromodomain inhibitors
MX370535B (es) 2013-11-18 2019-12-17 Forma Therapeutics Inc Compuestos de tetrahidroquinolina como inhibidores del bromodominio extra terminal y bromo (bet) y el uso de los mismos en el tratamiento de cáncer.
NZ739226A (en) 2015-07-22 2022-11-25 Enanta Pharm Inc Benzodiazepine derivatives as rsv inhibitors
TN2018000276A1 (en) 2016-02-05 2020-01-16 Denali Therapeutics Inc Inhibitors of receptor-interacting protein kinase 1.
HUE058802T2 (hu) 2016-12-09 2022-09-28 Denali Therapeutics Inc RIPK1 inhibitorokként alkalmas vegyületek
JP7076459B2 (ja) 2017-02-16 2022-05-27 エナンタ ファーマシューティカルズ インコーポレイテッド ベンゾジアゼピン誘導体の製造プロセス
WO2018226801A1 (en) * 2017-06-07 2018-12-13 Enanta Pharmaceuticals, Inc. Aryldiazepine derivatives as rsv inhibitors
WO2019006295A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
WO2019006291A1 (en) 2017-06-30 2019-01-03 Enanta Pharmaceuticals, Inc. HETEROCYCLIC COMPOUNDS AS RSV INHIBITORS
AU2018339068B2 (en) 2017-09-29 2022-12-15 Enanta Pharmaceuticals, Inc. Combination pharmaceutical agents as RSV inhibitors
US10647711B2 (en) 2017-11-13 2020-05-12 Enanta Pharmaceuticals, Inc. Azepin-2-one derivatives as RSV inhibitors
US10975094B2 (en) 2018-04-11 2021-04-13 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as RSV inhibitors
MX2021011144A (es) 2019-03-18 2022-01-18 Enanta Pharm Inc Derivados de las benzodiazepinas como inhibidores del vsr.
WO2020210246A1 (en) 2019-04-09 2020-10-15 Enanta Pharmaceuticals, Inc, Heterocyclic compounds as rsv inhibitors
US11505558B1 (en) 2019-10-04 2022-11-22 Enanta Pharmaceuticals, Inc. Antiviral heterocyclic compounds
UY39032A (es) 2020-01-24 2021-07-30 Enanta Pharm Inc Compuestos heterocíclicos como agentes antivirales
US11534439B2 (en) 2020-07-07 2022-12-27 Enanta Pharmaceuticals, Inc. Dihydroquinoxaline and dihydropyridopyrazine derivatives as RSV inhibitors
WO2022086840A1 (en) 2020-10-19 2022-04-28 Enanta Pharmaceuticals, Inc. Heterocyclic compounds as anti-viral agents
IL314082A (en) 2022-01-12 2024-09-01 Denali Therapeutics Inc Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2641280B1 (fr) * 1988-12-29 1994-01-21 Roussel Uclaf Nouveaux derives de la 2,4-dioxo 2,3,4,5-tetrahydro 1h-1,5-benzodiazepine, leur procede de preparation et leur application comme medicaments
FR2659653B1 (fr) * 1990-03-13 1992-05-22 Rhone Poulenc Sante Derives de l'uree, leur preparation et les medicaments les contenant.
US5206234A (en) * 1990-10-22 1993-04-27 Merck & Co., Inc. Benzolactam analogs as antagonists of cck
JP2904941B2 (ja) * 1991-01-28 1999-06-14 出光興産株式会社 スチレン系重合体の精製方法
GB9201180D0 (en) * 1992-01-21 1992-03-11 Glaxo Group Ltd Chemical compounds
CZ286764B6 (en) * 1994-04-14 2000-06-14 Glaxo Wellcome Inc 5-Heterocyclo-1,5-benzodiazepine derivatives, process of their preparation and pharmaceutical preparation containing thereof

Also Published As

Publication number Publication date
MY112237A (en) 2001-05-31
PE50994A1 (es) 1995-01-06
JPH08508744A (ja) 1996-09-17
NO954090L (no) 1995-12-13
AP512A (en) 1996-07-29
ECSP941066A (es) 1994-11-16
HU223467B1 (hu) 2004-07-28
OA10355A (en) 2001-10-19
RU2135486C1 (ru) 1999-08-27
AP9400635A0 (en) 1994-04-30
PE50594A1 (es) 1995-01-06
PL178790B1 (pl) 2000-06-30
US5646140A (en) 1997-07-08
ZA942571B (en) 1994-11-11
PT694039E (pt) 2001-06-29
HUT74102A (en) 1996-11-28
HU9502978D0 (en) 1995-12-28
IL109316A (en) 1999-03-12
CN1120843A (zh) 1996-04-17
US5585376A (en) 1996-12-17
WO1994024149A1 (en) 1994-10-27
EP0694039B1 (en) 2001-01-24
PH30897A (en) 1997-12-23
EP0694039A1 (en) 1996-01-31
AP462A (en) 1996-02-19
MY131569A (en) 2007-08-30
FI954853A (fi) 1995-10-12
PL311084A1 (en) 1996-02-05
NO311133B1 (no) 2001-10-15
AU681139B2 (en) 1997-08-21
NZ265272A (en) 1997-07-27
DE69426624T2 (de) 2001-06-21
HK1003943A1 (en) 1998-11-13
FI954853A0 (fi) 1995-10-12
CN1058487C (zh) 2000-11-15
GB9307833D0 (en) 1993-06-02
CA2158973C (en) 2006-06-06
DK0694039T3 (da) 2001-05-21
TW487703B (en) 2002-05-21
SK125395A3 (en) 1996-06-05
KR100364948B1 (ko) 2003-03-29
GR3035641T3 (en) 2001-06-29
ES2154674T3 (es) 2001-04-16
IS4148A (is) 1994-10-16
IL109316A0 (en) 1994-07-31
SK281211B6 (sk) 2001-01-18
CZ267595A3 (en) 1996-04-17
DE69426624D1 (de) 2001-03-01
NO954090D0 (no) 1995-10-13
CZ286695B6 (en) 2000-06-14
ATE198894T1 (de) 2001-02-15
CA2158973A1 (en) 1994-10-27
AP9400634A0 (en) 1994-04-30
ZA942570B (en) 1994-11-11
AU6567694A (en) 1994-11-08
JP3406317B2 (ja) 2003-05-12
IL109315A0 (en) 1994-07-31

Similar Documents

Publication Publication Date Title
IS4147A (is) Aðferð til framleiðslu á 1,5 Benzodiazepine afleiðum
IS4201A (is) Aðferð til framleiðslu á Benzofuran afleiðum
IS3970A (is) Hliðstæð aðferð til framleiðslu á 1,5-benzódíazepín afleiðum
IS4121A (is) Hliðstæð aðferð til framleiðslu á 2,6-Díamínópúrín afleiðum
IS3915A (is) Aðferð til framleiðslu á benzanilíð afleiðum
IS3914A (is) Aðferð til framleiðslu á benzanilíð afleiðum
MX9206450A (es) Proceso para la produccion de isoleucina-l.
IS3994A (is) Hliðstæð aðferð til framleiðslu á indole afleiðum
NO992860L (no) FremgangsmÕte for fremstilling av hydrokarboner
NO981800D0 (no) FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
HUP9901285A3 (en) Process for the production of difluoromethane
IS3827A (is) Hliðstæð aðferð við framleiðslu á pýrról[2,3 b]pýridínum
IS1951B (is) Aðferð til framleiðslu á pýrazóló[4,3-d]pýrimidín-7-ónum og milliefnum af því
GR3032600T3 (en) Process for the production of imidazo-benzodiazepine derivatives
IS4190A (is) Hliðstæð aðferð til framleiðslu á 1,5 bensódíasepín afleiðum
HUP9904096A3 (en) Process for the production of substituted phenylpyridines
ZA985918B (en) Process for the production of indole derivatives.
FI973644A (fi) Uusi menetelmä 2,3-dihydrobentsofuranolijohdannaisten valmistamiseksi
NO985535D0 (no) FremgangsmÕte for fremstilling av 1,3-alkandioler
FI960332A0 (fi) Menetelmä substituoitujan 4,6-diamino-5-syanopyrinidiinien valmistamiseksi
FR2686898B1 (fr) Methode de production de la l-phenylalanine.
IS2201B (is) Aðferð til framleiðslu á handhverfu auðguðum N-afleiddum laktömum
IS4707A (is) Aðferð til framleiðslu á díoxóazabísýklóhexönum
ZA924595B (en) Process for the production of 1-(n)-acetyl-3,5,7-trinitrocyclotetramethylenetetramine
NO179101C (no) Fremgangsmåte for fremstilling av dibeskyttet 2,3-hydroksymetyl-cyklobutanol